ArticlePharmaceutical medicine2017

Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey.

Kimberly H Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.